Dr. Reddy's Laboratories Limited · RDY · FY2027 Q2 · Calendar Q4 2026
Dr. Reddy’s: Mix-led margin gains and semaglutide rollout
The quarter supports a constructive operating thesis: core generics growth, mix-driven margin improvement, semaglutide expansion, biosimilar progress and CDMO development provide several potential growth drivers. The evidence is not one-sided, with regulatory timing, input costs, competition and weaker PSAI and European performance still requiring monitoring.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about RDY FY2027 Q2
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior quarter, the semaglutide supply problem was described as resolved rather than an active near-term constraint, while the current analysis emphasized 20.6% EBITDA margin, a broader rollout plan across 89 markets and progress in biosimilars and CDMO. Guidance sentiment remained maintained, with capex moving lower.
Guidance delta
Maintained overall guidance; management lowered FY27 capex guidance and continues to target higher profitability.
Key takeaways
- Management described revenue as broadly flat year over year but sequentially higher, with core generics growing at double-digit rates.
- EBITDA margin improved to 20.6%, which management attributed to product mix and cost discipline.
- The semaglutide API scale-up issue was described as resolved, with rollout planned across 89 markets by the end of 2026.
- The biosimilar pipeline advanced, including abatacept, rituximab and nivolumab programs.
- Management highlighted CDMO growth, partnerships and a lower FY27 capex outlook.
Management priorities
- Execute the semaglutide rollout across 89 markets.
- Advance abatacept, rituximab and nivolumab biosimilar milestones.
- Launch additional complex injectable generics in the second half of FY27.
- Expand CDMO capacity and pursue contract wins.
- Hold SG&A near 32% of revenue while improving EBITDA margin.
Follow RDY with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationDr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under a proprietary brand or as generic formulations that are therapeutically identical to their branded equivalents. This segment also includes the company's biologics ventures. The Pharmaceutical Services and Active Ingredients (PSAI) division focuses on producing and distributing active pharmaceutical ingredients (APIs) and chemical intermediates, which serve as crucial building blocks for final drug products.…
Historical context
All RDY earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| DGX Quest Diagnostics Incorporated | FY2026 Q3 · Calendar Q4 2026 | +4.5% | +1.8% | Quest Diagnostics: growth broadens, but PAMA remains a headwind |
| ARGX argenx SE | FY2026 Q3 · Calendar Q4 2026 | — | -1.6% | argenx: VYVGART momentum and a broader late-stage pipeline |
| MEDP Medpace Holdings, Inc. | FY2026 Q3 · Calendar Q4 2026 | +9.0% | -1.3% | Medpace: Record awards lift backlog as 2026 outlook improves |
| MOH Molina Healthcare, Inc. | FY2026 Q3 · Calendar Q4 2026 | +12.7% | +0.8% | Molina reaffirms 2026 outlook as Florida contract scales |
Latest beats and misses
Who reports nextBeat on EPS
- FIXFY2026 Q3 · October 22, 2026+8.2% EPS-8.5% move
- DECKFY2027 Q2 · October 22, 2026+13.4% EPS-0.2% move
- OMCFY2026 Q3 · October 22, 2026+2.2% EPS+2.6% move
- SSNCFY2026 Q3 · October 22, 2026+0.6% EPS+2.8% move
- BEFY2026 Q3 · October 22, 2026+36.0% EPS-8.7% move
- ROPFY2026 Q3 · October 22, 2026+1.7% EPS+9.7% move
Missed on EPS
- SNAFY2026 Q3 · October 22, 2026-5.9% EPS-3.4% move
- SPOTFY2026 Q3 · October 22, 2026-11.6% EPS+11.1% move
- VRSNFY2026 Q3 · October 22, 2026-2.0% EPS-0.9% move
- HBANMFY2026 Q3 · October 22, 2026-5.3% EPS+0.5% move
- HBANPFY2026 Q3 · October 22, 2026-5.3% EPS0.0% move
- PCGFY2026 Q3 · October 22, 2026-0.8% EPS-1.3% move
Get the RDY recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-10-23T17:03:07.130029+00:00
- FN2 earnings calendar · 2026-10-23T01:23:12.835668+00:00
- Polygon adjusted daily market bars · 2026-10-23T17:10:45.956005+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-23T17:10:45.953414+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-23. For educational purposes only; not investment advice.